好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Intramedullary spinal neurocysticercosis
Infectious Disease
P5 - Poster Session 5 (5:30 PM-6:30 PM)
4-031

Present an uncommon manifestation of neurocysticercosis and demonstrate its potential prognosis with appropriate treatment

Neurocysticercosis is the most common parasitic infection of the brain. Endemic areas include sub-Saharan Africa, Latin America, and East and South Asia. Spinal involvement is uncommon (< 3% of cases) with intramedullary lesions being the least common.

Case report

A 60-year-old man with no significant past medical history presented to University Teaching Hospital in Zambia with 9 months of progressive lower extremity weakness and numbness and bowel/bladder incontinence. Neurologic exam demonstrated spastic paraplegia and mid-thoracic sensory level.  MRI without contrast showed a thoracic intramedullary cystic lesion as well as similar lesions in the subcutaneous tissues.  Albendazole, praziquantel, and prednisone treatment for spinal neurocysticercosis was initiated for two weeks with marked improvement of strength over time. At follow-up six months later, strength was 3-4/5 in all muscle groups with persistent spasticity and moderately improved sensory deficits.  He was able to ambulate short distances with a cane.

Intramedullary spinal neurocysticercosis may present with severe disability, but dramatic recovery is possible with appropriate diagnosis and initiation of therapy.  Subtle imaging findings, such as the presence of subcutaneous cysts as seen in this patient, can provide important clues to this diagnosis.  While thought to be rare, it is also possible that this form of neurocysticercosis is underdiagnosed due to limitations in spinal imaging and neurological expertise in many settings where this infection is common.  

Authors/Disclosures
Jacob Manske, MD (University of Minnesota)
PRESENTER
No disclosure on file
Courtney M. Hrdlicka, MD (Mayo Clinic Arizona) Dr. Hrdlicka has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genomadix.
No disclosure on file
Omar Siddiqi, MD (Beth Israel Deaconess Medical Center) The institution of Dr. Siddiqi has received research support from NIH.
Deanna Saylor, MD, MHS (Johns Hopkins Hospital) Dr. Saylor has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. The institution of Dr. Saylor has received research support from National Institutes of Health. The institution of Dr. Saylor has received research support from 好色先生. Dr. Saylor has a non-compensated relationship as a Member of multiple committees and task forces focused on improving access to MS medications to people across the world with Multiple Sclerosis International Federation that is relevant to AAN interests or activities. Dr. Saylor has a non-compensated relationship as a Member of the Neurology and COVID19 committee with World Health Organization that is relevant to AAN interests or activities. Dr. Saylor has a non-compensated relationship as a Member of the International Outreach Committee, Junior and Early Career Membership Committee, and 好色先生al Innovation Commitees with American Neurological Association that is relevant to AAN interests or activities.